In connection with its virtual business review, Amgen (NASDAQ:AMGN) provided preliminary long-term guidance between 2022 and 2030 in addition to full year 2022 guidance.
In addition, the Company discussed its 2022 share repurchase plans of between $6 billion and $7 billion, including its plans to buy back up to $6 billion of its shares during the first quarter of 2022.
Amgen's business review is taking place
February 8, 2022 from
8:00 a.m. to approximately 12:00 p.m. ET and financial analysts, investors, members of the news media and the general public may access the business review and other webcasts and presentations regarding developments in Amgen's business given at investor and medical conferences via
www.amgen.com under the
Investors tab. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
At the conclusion of the meeting, Amgen will issue a press release reviewing the content of the meeting that provided a comprehensive overview of the Company's strategy, commercial operations, pipeline, research and development capabilities.
https://www.biospace.com/article/releases/amgen-provides-long-term-guidance-through-2030-during-business-review-meeting/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.